Published in Vaccine Weekly, September 7th, 2005
In a recent report published in the Journal of Clinical Oncology, researchers in Canada conducted a study "to describe the response rate and survival of children and adolescents with unresected or metastatic NRSTS treated with vincristine, ifosfamide, and doxorubicin."
"Between September 1996 and June 2000, 39 eligible patients received vincristine (1.5 mg/m2 weekly for 13 doses), ifosfamide (3 g/m2 daily for 3 days every 3 weeks for 7 cycles), doxorubicin (30...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.